AzTrials
AzTrials

HealthyNCT02409927

Effect of MCT Emulsification on Ketogenesis in Human Adults

A study testing MCT oil 10g, MCT homogenate 10g and MCT oil 20g in people with Healthy, run by Université de Sherbrooke.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Lower brain glucose uptake is present before the onset of cognitive deterioration and may increase the risk of cognitive decline in Alzheimer's disease. Ketones are the brain's main alternative energy substrates. Medium-chain triglycerides (MCT) are rapidly beta-oxidized and are ketogenic. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
MCT oil 10g, MCT homogenate 10g and MCT oil 20g
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
No sites listed yet
Study dates
Jul 2013to Sep 2014
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • aged 18 years or more

Who cannot join

  • smoker
  • pregnancy or breastfeeding
  • diabetes or insulin resistance
  • uncontrolled thyroid disease, hepatic or renal disease
  • uncontrolled high blood pressure
  • medical treatment influencing lipid or glucide metabolism
Show all 9Show fewer
  • ongoing or past severe drug or alcohol abuse
  • dementia or psychiatric difficulties or depression
  • chronic immune condition or inflammation

About this study

Official title: Effect of Medium-chain Triglycerides Emulsification on Ketogenesis and Adverse Effects in Human Adults

Lower brain glucose uptake is present before the onset of cognitive deterioration and may increase the risk of cognitive decline in Alzheimer's disease. Ketones are the brain's main alternative energy substrates. Medium-chain triglycerides (MCT) are rapidly beta-oxidized and are ketogenic. Large doses of MCT oil are linked to gastro-intestinal side effects due to incomplete absorption so the investigators examined whether homogenisation into a skim milk matrix (MCT-H) would both improve ketogenesis and reduce side-effects compared to MCT taken without homogenisation into a matrix (bulk MCT [MCT-B]).

Hypotheses: (i) MCT-H will be better absorbed compared to MCT-B, so MCT-H will result in higher ketonemia and lower side effects in healthy adults. (ii) The effects of MCT-B and MCT-H on ketogenesis will be dose-dependent.

Conditions
Healthy
Being tested
MCT oil 10g, MCT homogenate 10g, Control, MCT oil 20g, MCT homogenate 20g
Keywords
Medium-chain triglycerides, Metabolism, Ketones, Lipids, Emulsification
Medical subject headings
Ketosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MCT oil 10gDietary supplement

    10 g of pure MCT oil mixed with skim milk in a standardized breakfast

  • MCT homogenate 10gDietary supplement

    10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast

  • ControlDietary supplement

    vehicule (skim milk) with a standardized breakfast

  • MCT oil 20gDietary supplement

    20g of pure MCT oil mixed with skim milk in a standardized breakfast

  • MCT homogenate 20gDietary supplement

    20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast

  • MCT oil 30gDietary supplement

    30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast

  • MCT homogenate 30gDietary supplement

    30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast

Study groups in NCT02409927
Study groupRoleWhat they receive
Healthy participantOtherEach participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
Receives: Dietary Supplement: MCT oil 10g; Dietary Supplement: MCT homogenate 10g; Dietary Supplement: Control; Dietary Supplement: MCT oil 20g; Dietary Supplement: MCT homogenate 20g; Dietary Supplement: MCT oil 30g; Dietary Supplement: MCT homogenate 30g

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma Ketone Concentration

    Average of total ketones (beta-hydroxynutyrate + acetoacetate) measured in plasma, measured every 30 minutes for hours following intake of the different supplements

    Measured: Average of every 30 minutes for 4 hours following intake of supplement

Secondary outcomes (4)
  1. Plasma Glucose Concentration

    average of glucose measured every 30 minutes during the four hour of each metabolic day

    Measured: Average of every 30 minutes for 4 hours following intake of supplement

  2. Plasma Free Fatty Acids Concentration

    average of free fatty acids measured every 30 minutes during the four hour fo each metabolic day

    Measured: average of 4 hours following intake of supplement

  3. Plasma Insuline Concentration

    Average of insulin measured evey 30 minutes during the 4 hours of each metabolic day

    Measured: average of 4 hours following intake of supplement

  4. Number of Participants With Side Effects for Each Visit

    If participant had any side effect (mild or moderate) at least one time during the day.

    Measured: During the 4 hours following intake of supplement

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Apr 2015 (estimated)
  2. Study startJul 2013
  3. Primary completionSep 2014
  4. Study completionSep 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
Each participant underwent 7 metabolic day (1-day visit), each visit separate by a minimum of 3 day
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02409927
Sponsor's protocol ID
2014-391
Status last verified
May 2015
First submitted
27 Mar 2015
Last updated
11 Feb 2019
Data monitoring committee
No

Publications

  • Courchesne-Loyer A, Lowry CM, St-Pierre V, Vandenberghe C, Fortier M, Castellano CA, Wagner JR, Cunnane SC. Emulsification Increases the Acute Ketogenic Effect and Bioavailability of Medium-Chain Triglycerides in Humans: Protein, Carbohydrate, and Fat Metabolism. Curr Dev Nutr. 2017 Jun 21;1(7):e000851. doi: 10.3945/cdn.117.000851. eCollection 2017 Jul.

    PubMed 29955713

Questions about this trial

What is this clinical trial studying?

A study testing MCT oil 10g, MCT homogenate 10g and MCT oil 20g in people with Healthy, run by Université de Sherbrooke.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Dec 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma Ketone Concentration (time frame: Average of every 30 minutes for 4 hours following intake of supplement). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02409927, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2019; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in